Showing results (421-430 of 426) with videos related to
Sort By:
Pageof 43
You have reached the last page of results.This site can display upto 426 results.
Cancer|June 27, 2025
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment ConsortiumMichael Boyiadzis, Andrew H Wei, Bruno Paiva, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|December 17, 2010
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMosL-A Fraser, L Langsetmo, C Berger, et al.Blood|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myelomaOla Landgren, Thomas J Prior, Tara Masterson, et al.Chemical Communications (Cambridge, England)|June 9, 2020
An ethylene cross-bridged pentaazamacrocycle and its Cu2+ complex: constrained ligand topology and excellent kinetic stabilityAnthony D Shircliff, Benjamin P Burke, Dustin J Davilla, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized TrialsQian Shi, Bruno Paiva, Levi D Pederson, et al.Blood|September 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 studyAjai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria, et al.Pageof 43